Media release

From: Proteomics International Laboratories Ltd (ASX:PIQ)

A predictive test for chronic kidney disease in type 2 diabetes (DKD) to be available to Australian healthcare professionals from today.

Fast Facts About Diabetic Kidney Disease (DKD)

• A Serious Complication: DKD is a major complication of diabetes, affecting kidney function and increasing health risks
• Significant Health Impact: With over 1.5 million Australians living with diabetes and nearly half at risk of kidney disease
• Severe Consequences: If left unchecked, DKD can lead to dialysis or kidney transplant

Australian medical technology Company, Proteomics International has announced the official launch of its predictive test for diabetic kidney disease, in Australia. The launch coincides with World Kidney Day (13^th March 2025), a global event dedicated to raising awareness about the importance of kidney health and the urgent need for improved prevention, early diagnosis, and treatment of kidney diseases.

Clinical studies show the blood test can predict the risk of developing chronic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. This early warning provides healthcare professionals with a critical window to intervene, enabling better patient management and reducing the risk of severe kidney complications, including kidney failure and the need for dialysis or transplant.

Diabetes is the leading cause of chronic kidney disease globally, and the burden is particularly acute in Australia, where more than 1.5 million people are living with diabetes [1]. According to recent research, approximately one in two adults with diabetes will develop kidney disease [2], posing a significant threat to both quality of life and healthcare resources.

The commercial launch of the blood test into its home market is a key milestone in Proteomics International’s global commercialisation strategy.

Proteomics International Managing Director Dr Richard Lipscombe said, “We are excited to officially launch PromarkerD in Australia, particularly on World Kidney Day, which underscores the importance of early diagnosis and prevention. Diabetic kidney disease is a major public health challenge, and PromarkerD offers a highly innovative, accurate, and accessible way to identify those most at risk. By enabling proactive management, we aim to reduce the personal and financial costs associated with this life-threatening condition.”

Commercial Pathway in Australia

Proteomics International is engaging with key stakeholders across primary care networks, diabetes clinics, and professional bodies to support widespread adoption of the blood test across Australia. The Company will now collaborate with health insurers, patient advocacy groups, and government bodies to explore potential reimbursement pathways, aiming to make the test (priced at AUS $245) accessible to all Australians living with diabetes.

Proteomics International remains committed to leveraging its innovative Promarker® platform to bring its suite of precision diagnostic tests to the clinic.

---------

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), is a pioneer in precision diagnostics, based in Perth.

Disclaimer: PromarkerD is for healthcare professional use only. Proteomics International recommends that patients concerned about DKD seek advice from their doctors.

References

[1] https://www.aihw.gov.au/reports/diabetes/diabetes/contents/summary#prevalence

[2] International Diabetes Federation 2021

END